Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Alternative Names: ARQ 252 active ingredient - Jiangsu Hengrui Medicine; Ivarmacitinib sulfate - Arcutis Biotherapeutics/Reistone Biopharma; SHR-0302; SHR0302 base

Latest Information Update: 20 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antirheumatics; Cyclopentanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II/III Ankylosing spondylitis; Vitiligo
  • Phase II Alopecia areata; Crohn's disease
  • Phase I Liver disorders
  • Research Systemic lupus erythematosus

Most Recent Events

  • 07 Jun 2022 Jiangsu HengRui Medicine plans a pharmacokinetic phase I trial in Rheumatoid arthritis (In volunteers, Combination therapy, Monotherapy) (PO, Tablet), in June 2022 (NCT05404724)
  • 10 May 2022 Jiangsu HengRui Medicine plans a phase III drug-drug interaction trial in rheumatoid arthritis (In volunteers) in June 2022 (PO, Tablet) (NCT05392127)
  • 03 May 2022 Phase-III clinical trials in Ulcerative colitis (In adults, In the elderly) in USA, China, Ukraine and Georgia (PO) (Jiangsu Hengrui Medicine pipeline, May 2022) (NCT05181137)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top